3,4-dihydroxyphenylethanol has been researched along with Hepatitis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Álvarez, D; Bustamante, A; Echeverría, F; Espinosa, A; Gonzalez-Mañan, D; Ortiz, M; Soto-Alarcon, SA; Valenzuela, R; Videla, LA | 1 |
| Calignano, A; Canani, RB; Di Guida, F; Lama, A; Magliocca, S; Meli, R; Mollica, MP; Paciello, O; Pagano, TB; Pirozzi, C; Raso, GM; Russo, R; Simeoli, R | 1 |
2 other study(ies) available for 3,4-dihydroxyphenylethanol and Hepatitis
| Article | Year |
|---|---|
Reduction of high-fat diet-induced liver proinflammatory state by eicosapentaenoic acid plus hydroxytyrosol supplementation: involvement of resolvins RvE1/2 and RvD1/2.
Topics: Animals; Diet, High-Fat; Dietary Supplements; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fatty Acids; Hepatitis; Liver; Male; Mice, Inbred C57BL; NF-kappa B; Phenylethyl Alcohol | 2019 |
Hydroxytyrosol prevents metabolic impairment reducing hepatic inflammation and restoring duodenal integrity in a rat model of NAFLD.
Topics: Animals; Disease Models, Animal; Duodenum; Hepatitis; Male; Non-alcoholic Fatty Liver Disease; Phenylethyl Alcohol; Rats | 2016 |